Top

Published in:

01-12-2011

Tolvaptan for Heart Failure Patients with Volume Overload

Author: Masatsugu Hori

Published in: Cardiovascular Drugs and Therapy | Special Issue 1/2011

Excerpt

Edema is defined as a state of extracellular fluid accumulation, mostly of intercellular fluid, and clinically as a state where the subcutaneous tissues become enlarged because of the accumulation of interstitial fluid. Edema is often observed in daily clinical practice and the most serious causes include heart failure (HF), hepatic cirrhosis, and nephrotic syndrome. …

Japanese Circulation Society. Guidelines for the diagnosis and treatment of cardiovascular disease (Joint Study Gr oup Report 2004): guidelines for the diagnosis and treatment of chronic heart failure (revised 2005). http://www.j-circ.or.jp/guideline/pdf/JCS2005_matsuzaki_h.pdf. Accessed 27 Oct 2010.

Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577–85.PubMedCrossRef

Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785–91.PubMedCrossRef

Rivera-Santos A, Star R. Sodium: volume depletion and hyponatremia. In: Seldin D, Giebisch G, editors. Diuretic agents—clinical physiology and pharmacology. San Diego: Academic; 1997. p. 559–69.

Palmer BF. Potassium disturbances associated with the use of diuretics. In: Seldin D, Giebisch G, editors. Diuretic agents—clinical physiology and pharmacology. San Diego: Academic; 1997. p. 571–83.

Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.PubMedCrossRef

Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.PubMedCrossRef

Adrogué HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342:1581–9.PubMedCrossRef

Cuffe MS, Califf RM, Adams KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287:1541–7.PubMedCrossRef

10.

Kim SR, Hasunuma T, Sato O, et al. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V₂-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. Cardiovasc Drugs Ther. 2011; submitted.

11.

Matsuzaki M, Hori M, Izumi T, et al. Effects of tolvaptan on volume overload in Japanese patients with heart failure: Results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Cardiovasc Drugs Ther. 2011; submitted.

12.

Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST Study). Cardiovasc Drugs Ther. 2011; submitted.

13.

Fukunami M, Matsuzaki M, Hori M, et al. Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study. Cardiovasc Drugs Ther. 2011; submitted.

14.

Inomata T, Izumi T, Matsuzaki M, et al. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther. 2011; submitted.

15.

Onogawa T, Sakamoto Y, Nakamura S, et al. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther. 2011; submitted.

16.

Miyazaki T, Sakamoto Y, Yamashita T, et al. Anti-edematous effects of tolvaptan in experimental rodent models. Cardiovasc Drugs Ther. 2011; submitted.

17.

Furukawa M, Hirota M, Okumura H, et al. Nonclinical pharmacokinetics of tolvaptan. Cardiovasc Drugs Ther. 2011; submitted.

18.

Oi A, Ito N, Morishita K, et al. Nonclinical safety profile of tolvaptan. Cardiovasc Drugs Ther. 2011; submitted.

19.

Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther. 1998;287:860–7.PubMed

20.

Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials. Cardiovasc Drug Rev. 2007;25:1–13.PubMedCrossRef

21.

Hirano T, Yamamura Y, Nakamura S, Onogawa T, Mori T. Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats. J Pharmacol Exp Ther. 2000;292:288–94.PubMed

22.

Costello-Boerrigter LC, Smith WB, Boerrigter G, et al. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. Am J Physiol Ren Physiol. 2006;290:F273–8.CrossRef

Title: Tolvaptan for Heart Failure Patients with Volume Overload
Author: Masatsugu Hori
Publication date: 01-12-2011
Publisher: Springer US
Published in: Cardiovascular Drugs and Therapy / Issue Special Issue 1/2011
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI: https://doi.org/10.1007/s10557-011-6298-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Tolvaptan for Heart Failure Patients with Volume Overload

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2011

Erratum to: Tolvaptan for Heart Failure Patients with Volume Overload

Effects of Tolvaptan on Volume Overload in Japanese Patients with Heart Failure: Results of a Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study

Phase III Clinical Pharmacology Study of Tolvaptan

Efficacy and Safety of Tolvaptan in Heart Failure Patients with Sustained Volume Overload despite the Use of Conventional Diuretics: A Phase III Open-Label Study

Anti-edematous Effects of Tolvaptan in Experimental Rodent Models

Effects of Tolvaptan on Systemic and Renal Hemodynamic Function in Dogs with Congestive Heart Failure

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page